Tsuchiya Masami, Kikuchi Daisuke, Hatakeyama Shiro, Tasaka Yuichi, Uchikura Takeshi, Funakoshi Ryohkan, Obara Taku
Department of Pharmacy, Miyagi Cancer Center, Miyagi, Japan.
Laboratory of Biomolecule and Pathophysiological Chemistry, Tohoku University Graduate School of Pharmaceutical Sciences, Miyagi, Japan.
J Oncol Pharm Pract. 2025 Jul;31(5):803-809. doi: 10.1177/10781552241263997. Epub 2024 Jul 25.
IntroductionPharmacists are needed as members of oncology teams. The Japanese Society of Hospital Pharmacists (JSHP) conducts a nationwide survey annually to analyze the actual situation and generate fundamental information about hospital pharmacy practice in Japan. Using data from this large-scale survey, we described pharmacists' involvement in cancer chemotherapy. We explored the factors related to the acceleration of pharmacists' tasks or involvement in clinical practice, primarily in oncology.MethodsData were obtained from annual surveys conducted by JSHP from 2015 to 2020. All variables were expressed as categorical variables and tabulated. The Chi-square and Fisher's exact tests were used to compare the categorical variables. The Cochran-Armitage trend test was used to identify significant trends.ResultsFrom 2015 to 2020, 22,362 responses were recorded. After applying the exclusion criteria, 20,906 were analyzed. The proportion of hospitals enrolling pharmacists with oncology-related certifications significantly increased in all hospitals providing cancer care. Multivariable logistic regression analysis indicated that a smaller number of beds per pharmacist significantly correlated with additional fees for outpatient pharmacy services ( = 0.0002 for trend).ConclusionHospitals charging increased fees for outpatient oncology pharmacy services were associated with a smaller number of beds per pharmacist, regardless of hospital size. A balance between the number of beds and pharmacists, particularly certified oncology pharmacists, is crucial for safe and high-quality cancer treatment.
